Literature DB >> 21051677

Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.

Astrid Friebe1, Martin Horn, Folkhart Schmidt, Gesa Janssen, Monika-H Schmid-Wendtner, Matthias Volkenandt, Axel Hauschild, Charlie H Goldsmith, Martin Schaefer.   

Abstract

BACKGROUND: Adjuvant IFN-α treatment for patients with malignant melanoma is often complicated by depression. The influence of dosage, however, is unknown.
OBJECTIVE: The authors sought to elucidate this dosage effect.
METHOD: Using the Zung Self-Rating Depression Scale and the German Bf-S Self-Rating (Affectivity) Scale, the authors prospectively compared the frequency and severity of IFN-α-induced depressive symptoms between a group of 29 patients receiving low-dose and 17 patients getting high-dose induction therapy for 4 weeks.
RESULTS: Patients receiving high-dose induction treatment had significantly higher depression scores after 4 weeks, and significantly more patients in the high-dose group developed depression.
CONCLUSION: The authors concluded that frequency and severity of IFN-α-associated depression during melanoma treatment are dose-dependent.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051677     DOI: 10.1176/appi.psy.51.6.466

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  13 in total

1.  Parallel Effects of Methamphetamine on Anxiety and CCL3 in Humans and a Genetic Mouse Model of High Methamphetamine Intake.

Authors:  Marilyn Huckans; Clare J Wilhelm; Tamara J Phillips; Elaine T Huang; Rebekah Hudson; Jennifer M Loftis
Journal:  Neuropsychobiology       Date:  2018-01-18       Impact factor: 2.328

Review 2.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 3.  Do Statins Have Antidepressant Effects?

Authors:  Ole Köhler-Forsberg; Christiane Gasse; Michael Berk; Søren Dinesen Østergaard
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

4.  Psychological changes in melanoma patients during ipilimumab treatment compared to low-dose interferon alpha therapy-a follow-up study of first experiences.

Authors:  Péter Kovács; Gitta Pánczél; Kinga Borbola; Gabriella Juhász; Gabriella Liszkay
Journal:  Pathol Oncol Res       Date:  2014-04-27       Impact factor: 3.201

5.  The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.

Authors:  Howard L Kaufman; John M Kirkwood; F Stephen Hodi; Sanjiv Agarwala; Thomas Amatruda; Steven D Bines; Joseph I Clark; Brendan Curti; Marc S Ernstoff; Thomas Gajewski; Rene Gonzalez; Laura Jane Hyde; David Lawson; Michael Lotze; Jose Lutzky; Kim Margolin; David F McDermott; Donald Morton; Anna Pavlick; Jon M Richards; William Sharfman; Vernon K Sondak; Jeffrey Sosman; Susan Steel; Ahmad Tarhini; John A Thompson; Jill Titze; Walter Urba; Richard White; Michael B Atkins
Journal:  Nat Rev Clin Oncol       Date:  2013-08-27       Impact factor: 66.675

Review 6.  Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective.

Authors:  Krista M Rubin; Karen Vona; Kathleen Madden; Suzanne McGettigan; Ilana M Braun
Journal:  Support Care Cancer       Date:  2012-05-05       Impact factor: 3.603

Review 7.  Inflammation in Depression and the Potential for Anti-Inflammatory Treatment.

Authors:  Ole Kohler; Jesper Krogh; Ole Mors; Michael Eriksen Benros
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

8.  Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.

Authors:  Célia Fourrier; Emma Sampson; Natalie T Mills; Bernhard T Baune
Journal:  Trials       Date:  2018-08-20       Impact factor: 2.279

Review 9.  Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders.

Authors:  Rickinder Sethi; Nieves Gómez-Coronado; Adam J Walker; Oliver D'Arcy Robertson; Bruno Agustini; Michael Berk; Seetal Dodd
Journal:  Front Psychiatry       Date:  2019-09-04       Impact factor: 4.157

10.  Assigning Clinical Significance and Symptom Severity Using the Zung Scales: Levels of Misclassification Arising from Confusion between Index and Raw Scores.

Authors:  Debra A Dunstan; Ned Scott
Journal:  Depress Res Treat       Date:  2018-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.